AR095499A1 - ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b - Google Patents

ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b

Info

Publication number
AR095499A1
AR095499A1 ARP140101104A ARP140101104A AR095499A1 AR 095499 A1 AR095499 A1 AR 095499A1 AR P140101104 A ARP140101104 A AR P140101104A AR P140101104 A ARP140101104 A AR P140101104A AR 095499 A1 AR095499 A1 AR 095499A1
Authority
AR
Argentina
Prior art keywords
seq
amino acids
sequence
antibody comprises
antibody
Prior art date
Application number
ARP140101104A
Other languages
English (en)
Spanish (es)
Inventor
Hermiston Terry
Jin Ye
Murphy John
Dr Strerath Michael
Myles Timothy
Dr Dittmer Frank
Dr Gritzan Uwe
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR095499(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of AR095499A1 publication Critical patent/AR095499A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP140101104A 2013-03-14 2014-03-14 ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b AR095499A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361784590P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
AR095499A1 true AR095499A1 (es) 2015-10-21

Family

ID=50680168

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101104A AR095499A1 (es) 2013-03-14 2014-03-14 ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b

Country Status (18)

Country Link
US (4) US9593166B2 (enExample)
EP (1) EP2970500A1 (enExample)
JP (1) JP2016519081A (enExample)
KR (1) KR20150127202A (enExample)
CN (1) CN105229033B (enExample)
AR (1) AR095499A1 (enExample)
AU (1) AU2014236198A1 (enExample)
BR (1) BR112015021399A2 (enExample)
CA (1) CA2916421A1 (enExample)
HK (1) HK1215261A1 (enExample)
MX (1) MX2015012441A (enExample)
PE (1) PE20160533A1 (enExample)
RU (1) RU2015143696A (enExample)
SG (1) SG11201506886TA (enExample)
TW (1) TW201529602A (enExample)
UY (1) UY35457A (enExample)
WO (1) WO2014153195A1 (enExample)
ZA (1) ZA201507628B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9593166B2 (en) * 2013-03-14 2017-03-14 Bayer Healthcare Llc Monoclonal antibodies against antithrombin β
EP3146759B1 (en) * 2014-05-19 2021-04-07 Nokia Solutions and Networks Oy Re-establishment procedure in dual connectivity networks
CR20210429A (es) 2015-06-24 2021-09-24 Hoffmann La Roche ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
TWI819458B (zh) 2015-10-02 2023-10-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP2019516347A (ja) * 2016-03-18 2019-06-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 抗アンチトロンビン単一ドメイン抗体及びそれを含むポリペプチド

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5578253A (en) 1978-12-11 1980-06-12 Teikoku Hormone Mfg Co Ltd Immune measurement of hito antithrombin 3
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
BE896543A (fr) 1983-04-22 1983-08-16 Wallone Region Ensembles d'anticorps monoclonaux deriges contre les proteines humaines impliquees dans la coagulation et la fibrinolyse du sang
JPH0644876B2 (ja) 1985-12-13 1994-06-15 株式会社ヤトロン 抗トロンビン・アンチトロンビン３複合体モノクローナル抗体、及びその製造方法、並びにそれを用いるトロンビン・アンチトロンビン３複合体の免疫定量法、及びそれを用いるトロンビン・アンチトロンビン３複合体の精製方法
JPH0266458A (ja) 1988-09-01 1990-03-06 Takara Shuzo Co Ltd ビトロネクチン及びビトロネクチン‐トロンビン‐アンチトロンビン３複合体の測定方法
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU628960B2 (en) 1989-04-07 1992-09-24 Teijin Limited Method of immunologically assaying human thrombin- antithrombin III complex, assay reagent and kit therefor
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
JPH0694713A (ja) 1991-07-31 1994-04-08 Masashi Funayama アンチトロンビンｉｉｉ活性の測定方法とそれを用いたアンチトロンビンｉｉｉ活性の測定キット
JPH07238099A (ja) 1994-02-25 1995-09-12 Dai Ichi Pure Chem Co Ltd モノクローナル抗体及びこれを用いる免疫学的測定法
FR2718849B1 (fr) 1994-04-14 1996-06-14 Pasteur Sanofi Diagnostics Procédé d'immunodosage de l'antithrombine III activée par un glycosaminoglycane, anticorps monoclonaux correspondants et leur procédé d'obtention.
US5753445A (en) 1994-04-26 1998-05-19 The Mount Sinai Medical Center Of The City University Of New York Test for the detection of anti-heparin antibodies
JP3841364B2 (ja) 1994-10-18 2006-11-01 株式会社三菱化学ヤトロン 抗ヒトビトロネクチン・トロンビン・アンチトロンビンｉｉｉ 複合体モノクローナル抗体、ハイブリドーマ及び免疫学的測定方法
CN1201005C (zh) 1996-05-22 2005-05-11 维文蒂阿生物技术股份有限公司 特异性检测癌细胞的抗原结合片段、编码所述片段的dna、以及它们在预防和检测癌症上的用途
WO1997045538A1 (en) 1996-05-31 1997-12-04 Medigene Ag Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces
AU782069B2 (en) 1999-05-13 2005-06-30 Gtc Biotherapeutics, Inc. Transgenically produced antithrombin III and mutants thereof
JP2001321167A (ja) 2000-05-10 2001-11-20 Cosmo Research Inst モノクローナル抗体
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
JP2002316999A (ja) 2001-04-17 2002-10-31 Dai Ichi Pure Chem Co Ltd モノクローナル抗体
US20090226429A1 (en) 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
WO2003089575A2 (en) 2002-04-15 2003-10-30 Human Genome Sciences, Inc. Antibodies that specifically bind to tl5
EP1530629B1 (en) 2002-05-31 2011-08-31 The University of Utah Research Foundation Variants of antithrombin iii
EP1382615A1 (en) 2002-07-15 2004-01-21 Xerion Pharmaceuticals AG MCAM inhibitors
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
RU2262109C2 (ru) 2002-12-30 2005-10-10 Институт биохимической физики им. Н.М. Эмануэля Российской академии наук Способ определения концентрации антитромбина iii в плазме крови
DE602004025332D1 (de) 2003-03-14 2010-03-18 Wyeth Corp Antikörper gegen il21-rezeptor und deren verwendung
EP1633316A4 (en) 2003-05-06 2008-04-02 Human Genome Sciences Inc ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
GB2404981A (en) 2003-08-15 2005-02-16 Univ Geneve Diagnostic method for stroke
NZ547588A (en) 2003-11-07 2009-05-31 Immunex Corp Antibodies that bind interleukin-4 receptor
US7271245B2 (en) 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
JP4829609B2 (ja) 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
WO2006084050A2 (en) 2005-02-01 2006-08-10 Dyax Corp. Libraries and methods for isolating antibodies
DK2175877T3 (da) 2007-07-20 2012-04-16 Univ Paris Sud Xi Anvendelse af muterede antitrombiner til behandling eller forebyggelse af koagulationssygdomme
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
JP5539896B2 (ja) 2007-11-29 2014-07-02 グリフオルス・セラピユーテイクス・インコーポレーテツド 組換え的に改変されたプラスミン
ES2346618B1 (es) 2008-08-14 2011-08-03 Universidad De Murcia Anticuerpo monoclonal anti antitrombina citrulinada humana y sus usos.
NO330078B1 (no) 2008-09-22 2011-02-14 Optipro As Fremgangsmåte og apparat for å overvåke slitasje i sikteduker
US20110311550A1 (en) 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
WO2012033987A2 (en) 2010-09-09 2012-03-15 Purdue Research Foundation Anti-human folate receptor beta antibodies and methods of use
US20140356377A1 (en) * 2011-08-25 2014-12-04 Umc Utrecht Holding B.V. Compounds for use in boosting coagulation
CN103930595A (zh) 2011-11-11 2014-07-16 Sio2医药产品公司 用于药物包装的钝化、pH保护性或润滑性涂层、涂布方法以及设备
US9593166B2 (en) * 2013-03-14 2017-03-14 Bayer Healthcare Llc Monoclonal antibodies against antithrombin β
JP6094713B1 (ja) 2016-06-30 2017-03-15 富士ゼロックス株式会社 定着部材、定着装置、及び画像形成装置

Also Published As

Publication number Publication date
CA2916421A1 (en) 2014-09-25
US9908942B2 (en) 2018-03-06
SG11201506886TA (en) 2015-09-29
EP2970500A1 (en) 2016-01-20
PE20160533A1 (es) 2016-06-09
US20180244799A1 (en) 2018-08-30
CN105229033B (zh) 2019-04-23
CN105229033A (zh) 2016-01-06
AU2014236198A1 (en) 2015-10-15
RU2015143696A (ru) 2017-04-19
MX2015012441A (es) 2016-08-08
US20140271660A1 (en) 2014-09-18
US20160024222A1 (en) 2016-01-28
TW201529602A (zh) 2015-08-01
UY35457A (es) 2014-10-31
US9593166B2 (en) 2017-03-14
US20140271661A1 (en) 2014-09-18
BR112015021399A2 (pt) 2017-07-18
US10144784B2 (en) 2018-12-04
HK1215261A1 (zh) 2016-08-19
KR20150127202A (ko) 2015-11-16
JP2016519081A (ja) 2016-06-30
ZA201507628B (en) 2017-11-29
WO2014153195A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
AR105313A1 (es) Anticuerpo anti-cd137 terapéutico
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
AR106752A1 (es) Proteínas de unión a pd1 / ctla4
PE20240913A1 (es) Anticuerpos anti-il-2r agonistas y metodos de uso
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
AR099698A1 (es) Anticuerpos contra el c5 que tienen farmacocinética mejorada
AR109882A1 (es) Anticuerpos monoclonales neutralizantes anti-tl1a
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
AR104280A1 (es) Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
AR085955A1 (es) Proteinas de union al antigeno
SI2542257T1 (en) Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
AR087567A1 (es) Anticuerpos anti-tie2 y usos de los mismos
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
AR102592A1 (es) Anticuerpos biespecíficos y métodos de uso en oftalmología
PE20190920A1 (es) Anticuerpos modificados de union a fcrn humano y metodos de utilizacion

Legal Events

Date Code Title Description
FB Suspension of granting procedure